Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea.
- Author:
Dong Gun LEE
1
Author Information
- Publication Type:Review
- Keywords: Stem cell transplantation; Vaccination; Graft versus host disease; Immune response; Infection
- MeSH: Americas; Bone Marrow; Centers for Disease Control and Prevention (U.S.); Chickenpox; Communicable Diseases; Delivery of Health Care; Graft vs Host Disease; Haemophilus influenzae type b; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Influenza, Human; Korea; Measles; Mumps; Poliomyelitis; Rubella; Stem Cell Transplantation; Tetanus; Transplants; Vaccination
- From:Infection and Chemotherapy 2013;45(3):272-282
- CountryRepublic of Korea
- Language:English
- Abstract: Antibody titers to vaccine-preventable diseases such as tetanus, polio, measles, mumps, and rubella decline within 1-10 years after allogeneic or autologous hematopoietic stem cell transplantation (SCT) if the recipient is not vaccinated. Vaccine-preventable diseases such as pneumococcal diseases, Haemophilus influenzae type b infections, influenza, measles, and varicella can pose an increased risk for SCT recipients. Therefore, after SCT, the recipients should be routinely revaccinated. Vaccination recommendations have previously been developed and published by the European Group of Blood and Marrow Transplantation and the Centers for Disease Control, by the Infectious Diseases Society of America, and by the American Society for Blood and Marrow Transplantation in 2009. Different epidemiologies and strategies have existed in Korea. In 2012, the Korean Society of Infectious Diseases published "Vaccination for Adult" describing the guidelines for vaccination, one of the chapters assigned for vaccination of SCT recipients. The present article reviews the current available vaccination strategies for SCT recipients, their family members, and healthcare workers, with the focus on recent Korean perspectives.
